If we experience one or more of these events in the future, we may be required to implement expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

filing / Aug 6, 2026 / receipt

Over the past year, we took purposeful, disciplined actions to optimize our portfolio and continue to strengthen our commercial and development capabilities, including strategic transactions that expanded our presence across oncology, neurology and cardiology while diversifying our pipeline.

filing / Aug 6, 2026 / receipt

These decreases were offset by an increase in employee-related costs for the three and six months ended June 30, 2026, due to the increase in headcount from the Company’s business acquisitions in 2025.

filing / Aug 6, 2026 / receipt

• Our ability to continuously improve our operating efficiencies and control and reduce costs. Disruption in our financial performance could occur if we experience significant adverse changes in product or customer mix, significant changes in our competitive or regulatory environment, broad economic downturns, sustained inflation, adverse industry or company conditions or catastrophic external events, including pan

filing / Aug 6, 2026 / receipt

As a result, PYLARIFY TruVu has the potential to enhance supply flexibility and improve operating leverage across the network of PET manufacturing facilities (“PMFs”) that will manufacture and distribute the product.

filing / May 7, 2026 / receipt

If we experience one or more of these events in the future, we may be required to implement expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

filing / May 7, 2026 / receipt

Over the past year, we took purposeful, disciplined actions to optimize our portfolio and continue to strengthen our commercial and development capabilities, including strategic transactions that expanded our presence across oncology, neurology and cardiology while diversifying our pipeline.

filing / May 7, 2026 / receipt